Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Anthrax defenses need to be strengthened: Experts

It has been a decade since the anthrax attacks brought home the reality of bioterrorism and the nation now has a stockpile of some basic tools to fight back against a few of the threats that worry defense experts the most.

28 Sep 2011

Asthma patients admitted to hospital with H1N1 are half as likely to die from infection

People with asthma who are admitted to hospital with pandemic influenza H1N1 (swine flu) are half as likely to die or require intensive care than those without asthma, according to new research.

26 Sep 2011

Vaxent, PREVENT sign license agreement to develop and commercialize Strep-A vaccine

An international collaboration between Vaxent, a Memphis-based early stage vaccine development company in the Memphis Bioworks Foundation Incubator, and The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a Centre of Excellence for Commercialization and Research (CECR) in Saskatchewan, has put a vaccine for group A streptococcus (Strep-A) back on the path for potential commercialization.

26 Sep 2011

Scientists identify genetic variants associated with lung health

Scientists have for the first time discovered sixteen new sections of the genetic code that relate to lung health -- opening up the possibility for better prevention as well as treatment for lung diseases.

26 Sep 2011

New treatment concept for complex malaria

Team from the Medical University of Vienna, led by Harald Noedl from the Institute of Specific Prophylaxis and Tropical Medicine, is developing a new treatment concept for complex malaria in Bangladesh. This treatment is intended to significantly cut the mortality rate and could save the lives of tens of thousands of children.

23 Sep 2011

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

Astellas Pharma Europe Ltd. (APEL) and Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhoea (CDAD).

23 Sep 2011

Two TGen students receive SRP grants for antibiotic resistance and Alzheimer's research

Two Arizona university graduate students working at the Translational Genomics Research Institute (TGen) have each received $50,000 grants from the Salt River Project.

23 Sep 2011

'ResistanceMap' tracks antibiotic resistance online

"Extending the Cure," a research project of the Center for Disease Dynamics, Economics & Policy that looks at antibiotic resistance, on Wednesday launched a map "designed to be a tool for public health, researchers, doctors, the media and the public to track resistant pathogens, which is a growing problem around the world," the Washington Post's "The Checkup" blog reports.

22 Sep 2011

Aradigm announces two ciprofloxacin Phase 2b study data on non-CF bronchiectasis

Aradigm Corporation today announced it is presenting data on September 26, 2011, from its Phase 2b studies at the ERS Annual Congress in Amsterdam, Netherlands. The two podium presentations review the results from the Company's two clinical trials of inhaled ciprofloxacin in non-cystic fibrosis bronchiectasis (BE) patients.

22 Sep 2011

NIH to honor IGB faculty member with innovator award

Douglas A. Mitchell, IGB faculty member in the Mining Microbial Genomes for Novel Antibiotics research theme and assistant professor in the Department of Chemistry, is a recipient of the 2011 National Institutes of Health Director's New Innovator Award. The award recognizes bold ideas from some of the nation's most promising new scientists.

22 Sep 2011

ASU scientists receive USDA grants to combat food-related illness

Roughly 1 in six Americans are sickened every year by food-borne ailments, according to the Centers for Disease Control and Prevention. The effects of these illnesses range from acutely unpleasant to lethal, and the problem may be getting worse, as our food supply becomes more global, with an increasing number of antibiotic-resistant pathogens.

21 Sep 2011

Antivirals from shark cartilage compound squalamine

A unique compound originally isolated from sharks could prove to be a promising treatment for hepatitis B and C and other viral diseases, researchers say. Known as squalamine, the drug has not yet been tested as an antiviral agent in humans, but it has been given to hundreds of people enrolled in clinical trials designed to test its usefulness for other conditions. Researchers say they hope to begin human trials to test the compound’s antiviral activity within the next year.

21 Sep 2011

A code beyond DNA: Modified tRNA bases are characteristic of species

Our genetic code consists of four “letters” in the form of the nucleobases in our DNA and RNA. Three letters together form a “word” that are translated into an amino acid by tRNA and combined into proteins. Special markings subdivide the gene into active and inactive regions. A third possible level of information has so far received less attention: the chemical modification of tRNA nucleobases. In the journal Angewandte Chemie Thomas Carell and a team at the University of Munich have now demonstrated that tRNA modification profiles can be used for the characterization of species and the differentiation of pathogenic and nonpathogenic bacterial strains.

20 Sep 2011

FoxM1 protein plays a critical role in development of medulloblastomas

Medulloblastomas constitute the most frequent class of malignant childhood brain tumor. Tumors of this type arise due to the uncontrolled proliferation of immature nerve cells in the developing brain, and there is no targeted treatment available.

20 Sep 2011

Powerful new antibiotic treatment for MRSA and C. difficile bugs

MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly MRSA and Clostridium difficile (C. diff.) bugs.

20 Sep 2011

Additional data on safety, tolerability of Cempra's solithromycin to be presented at 51st ICAAC

Cempra Pharmaceuticals today announced abstracts to be presented on its fourth generation macrolide and novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17 to 20, 2011, in Chicago. The abstracts provide additional data that demonstrate the safety and routes of administration of CEM-101, a new generation macrolide.

17 Sep 2011

Researchers develop polymers that fluoresce in the presence of bacteria

Researchers at the University of Sheffield have developed polymers that fluoresce in the presence of bacteria, paving the way for the rapid detection and assessment of wound infection using ultra-violet light.

16 Sep 2011

New paper describes unique process that is central to induction of MSRA antibiotic resistance

A new paper by a team of University of Notre Dame researchers that included Shahriar Mobashery, Jeffrey Peng, Brian Baker and their researchers Oleg Borbulevych, Malika Kumararasiri, Brian Wilson, Leticia Llarrull, Mijoon Lee, Dusan Hesek and Qicun Shi describes a unique process that is central to induction of antibiotic resistance in the problematic bacterium methicillin-resistant Staphylococcus aureus.

16 Sep 2011

Longer looks: Fighting antibiotic resistance; a health care arms race video; the HVP debate

We won't stop the rising tide of infections until we develop a new business model to fight them. We are not quite on the brink of some dystopian Victorian future. But every year, the prognosis for infectious-disease patients gets a bit grimmer. … And more-powerful drugs tend to cost more than the old drugs. … Even in the rich world, death from infection still looms; MRSA alone kills thousands every year. And firms are not developing antibiotics as fast as they used to.

16 Sep 2011

Azithromycin gel may treat borreliosis in humans

Blood-sucking ticks are not just a nuisance, they can also transmit dangerous diseases. One of them is Lyme disease, which is caused by bacteria of the genus Borrelia, and requires a course of treatment with antibiotics lasting several weeks. LMU researchers have come up with a quicker alternative.

16 Sep 2011